MCID: INT007
MIFTS: 53

Intermediate Coronary Syndrome

Categories: Cardiovascular diseases

Aliases & Classifications for Intermediate Coronary Syndrome

MalaCards integrated aliases for Intermediate Coronary Syndrome:

Name: Intermediate Coronary Syndrome 12 15 17
Unstable Angina 12 15 32
Angina, Unstable 44 70
Myocardial Preinfarction Syndrome 70
Anginal Chest Pain at Rest 12
Impending Infarction 12
Preinfarction Angina 12
Worsening Angina 12
Angina at Rest 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8805
ICD9CM 34 411.1
MeSH 44 D000789
NCIt 50 C66911
SNOMED-CT 67 155308009
ICD10 32 I20.0
UMLS 70 C0002965 C0086666

Summaries for Intermediate Coronary Syndrome

MalaCards based summary : Intermediate Coronary Syndrome, also known as unstable angina, is related to coronary heart disease 1 and coronary thrombosis, and has symptoms including angina pectoris An important gene associated with Intermediate Coronary Syndrome is PF4 (Platelet Factor 4), and among its related pathways/superpathways are MicroRNAs in cancer and Folate Metabolism. The drugs Nicorandil and Fondaparinux have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and neutrophil, and related phenotypes are cardiovascular system and muscle

Related Diseases for Intermediate Coronary Syndrome

Diseases related to Intermediate Coronary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 468)
# Related Disease Score Top Affiliating Genes
1 coronary heart disease 1 32.1 PCSK9 INS CRP APOB ACE
2 coronary thrombosis 31.5 SELP P2RY12 ITGA2B F3 CRP
3 proteasome-associated autoinflammatory syndrome 1 31.0 SELP INS IL6 CRP
4 coronary artery vasospasm 31.0 TNNI3 CRP ACE
5 thrombosis 30.9 SELP PF4 P2RY12 ITGA2B F3
6 heparin-induced thrombocytopenia 30.9 PF4 F3
7 mitral valve insufficiency 30.9 TNNT2 TNNI3 MIR423 CRP ACE
8 pulmonary edema 30.9 TNNT2 TNNI3 CRP ACE
9 aortic aneurysm, familial abdominal, 1 30.8 MIR126 IL6 CRP ACE
10 subclavian steal syndrome 30.7 F3 CRP
11 mental depression 30.7 INS IL6 CRP
12 heart valve disease 30.6 TNNI3 MIR423 MIR126 CRP ACE
13 carotid stenosis 30.6 SELP CRP ACE
14 myocardial stunning 30.6 TNNT2 TNNI3 ACE
15 cardiac tamponade 30.6 TNNI3 F3 CRP ACE
16 mitral valve stenosis 30.6 SELP PF4 F3 CRP ACE
17 peripheral vascular disease 30.5 SELP PF4 IL6 F3 CRP APOB
18 thrombocytopenia 30.5 SELP PF4 P2RY12 ITGA2B IL6 F3
19 hypercholesterolemia, familial, 1 30.5 PCSK9 INS CRP APOB ACE
20 congestive heart failure 30.5 TNNT2 TNNI3 INS IL6 CRP ACE
21 urinary tract infection 30.5 CRP ACE
22 femoral neuropathy 30.4 MB F3
23 pericarditis 30.4 TNNT2 TNNI3 IL6 CRP ACE
24 essential thrombocythemia 30.4 SELP PF4 ITGA2B IL6 F3 CRP
25 systolic heart failure 30.4 IL6 CRP ACE
26 thrombocytosis 30.4 SELP PF4 IL6 F3 CRP
27 aortic valve insufficiency 30.4 TNNI3 F3 CRP ACE
28 endocarditis 30.4 TNNI3 PF4 IL6 CRP
29 antiphospholipid syndrome 30.3 SELP PF4 F3 CRP
30 inferior myocardial infarction 30.3 TNNI3 ACE
31 pulmonary hypertension 30.3 SELP IL6 F3 CRP ACE
32 esophageal disease 30.3 MIR423 MIR145 MIR126 MIR106B
33 atrial fibrillation 30.3 SELP PF4 CRP ACE
34 lung disease 30.3 INS IL6 F3 CRP ACE
35 intermittent claudication 30.3 TNNT2 SELP PF4 IL6 CRP ACE
36 bernard-soulier syndrome 30.3 SELP P2RY12 ITGA2B F3
37 background diabetic retinopathy 30.3 INS IL6 CRP ACE
38 kawasaki disease 30.2 MIR145 IL6 CRP
39 left bundle branch hemiblock 30.2 TNNT2 TNNT1 TNNI3 P2RY12 ITGA2B CRP
40 gas gangrene 30.2 TNNT2 TNNT1 TNNI3 MB IL6 CRP
41 familial hyperlipidemia 30.2 INS CRP APOB ACE
42 toxic shock syndrome 30.2 IL6 F3 CRP
43 lipid metabolism disorder 30.2 MIR126 INS IL6 CRP APOB ACE
44 microvascular complications of diabetes 1 30.2 SELP MIR423 INS IL6
45 angina pectoris 30.1 TNNI3 MB INS IL6 F3 CRP
46 hyperuricemia 30.1 INS CRP APOB
47 pulmonary embolism 30.1 TNNT2 TNNT1 TNNI3 MB F3 CRP
48 beta-thalassemia 30.1 INS IL6 CRP APOB
49 migraine with or without aura 1 30.1 INS IL6 CRP ACE
50 coronary stenosis 30.1 TNNI3 PCSK9 IL6 CRP APOB ACE

Comorbidity relations with Intermediate Coronary Syndrome via Phenotypic Disease Network (PDN): (show top 50) (show all 102)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Stress Disorder
Allergic Urticaria Angina Pectoris
Anthracosis Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Aortic Valve Disease 2
Asbestosis Atrioventricular Block
Atrophic Gastritis Basilar Artery Insufficiency
Benign Essential Hypertension Benign Hypertensive Renal Disease
Bleeding Disorder, Platelet-Type, 11 Bronchitis
Cardiac Arrest Cardiac Arrhythmia
Cardiogenic Shock Cerebrovascular Disease
Chronic Intestinal Vascular Insufficiency Chronic Kidney Disease
Constrictive Pericarditis Coronary Artery Aneurysm
Deficiency Anemia Diabetic Polyneuropathy
Diaphragm Disease Dressler's Syndrome
Duodenitis Dyskinesia of Esophagus
Dysthymic Disorder Esophagitis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Gallbladder Disease Gastroesophageal Reflux
Generalized Atherosclerosis Gout
Heart Disease Hemopericardium
Hyperlipoproteinemia, Type I Hyperlipoproteinemia, Type Iv
Hyperlipoproteinemia, Type V Hypertension, Essential

Graphical network of the top 20 diseases related to Intermediate Coronary Syndrome:



Diseases related to Intermediate Coronary Syndrome

Symptoms & Phenotypes for Intermediate Coronary Syndrome

UMLS symptoms related to Intermediate Coronary Syndrome:


angina pectoris

MGI Mouse Phenotypes related to Intermediate Coronary Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.7 ACE APOB CRP F3 IL6 INS
2 muscle MP:0005369 9.23 APOB F3 IL6 INS MB TNNI3

Drugs & Therapeutics for Intermediate Coronary Syndrome

Drugs for Intermediate Coronary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
2
Fondaparinux Approved, Investigational Phase 4 104993-28-4
3
Chromium Approved Phase 4 7440-47-3 27668
4
Abciximab Approved Phase 4 143653-53-6
5
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
6
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
7
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
8
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
9
Adenosine Approved, Investigational Phase 4 58-61-7 60961
10
Cangrelor Approved Phase 4 163706-06-7 9854012
11
Pravastatin Approved Phase 4 81093-37-0 54687
12
Simvastatin Approved Phase 4 79902-63-9 54454
13
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
14
Metformin Approved Phase 4 657-24-9 4091 14219
15
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
16
Methoxyflurane Approved, Investigational, Vet_approved Phase 4 76-38-0 4116
17
Morphine Approved, Investigational Phase 4 57-27-2 5288826
18
Cobalt Approved, Experimental Phase 4 7440-48-4 104729
19
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
20
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
21
Atorvastatin Approved Phase 4 134523-00-5 60823
22
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
23
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
24
Nitric Oxide Approved Phase 4 10102-43-9 145068
25
Trimetazidine Approved, Investigational Phase 4 5011-34-7
26
Ticagrelor Approved Phase 4 274693-27-5 9871419
27
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
28
Dalteparin Approved Phase 4 9005-49-6
29
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
30
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
31
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
32 Angelica Phase 4
33 Calamus Phase 4
34 Vitamin B9 Phase 4
35 Vitamin B Complex Phase 4
36 Folate Phase 4
37 Hypoglycemic Agents Phase 4
38 PENTA Phase 4
39 Hormone Antagonists Phase 4
40 Hormones Phase 4
41 polysaccharide-K Phase 4
42 Chinese Salvia Phase 4
43 Omega 3 Fatty Acid Phase 4
44 Eicosapentaenoic acid ethyl ester Phase 4
45 Gastrointestinal Agents Phase 4
46 Dopamine Agents Phase 4
47 Dopamine Antagonists Phase 4
48 Antiemetics Phase 4
49 Narcotic Antagonists Phase 4
50 Sitagliptin Phosphate Phase 4

Interventional clinical trials:

(show top 50) (show all 237)
# Name Status NCT ID Phase Drugs
1 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
2 Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina. Unknown status NCT03171597 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction;Gualou Xiebai Banxia Decoction & Danshen Decoction;Shuanghe Decoction
3 Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris: a Parallel, Double Blind, Randomized, Controlled, Multi-center Trial. Unknown status NCT03037047 Phase 4 0.9% Sodium Chloride Injection;salvianolate injection
4 A Prospective, Randomised, Open-labeled, Parallel Group Study to Assess the Efficacy and Safety of Low Dose Ticagrelor Compared With Standard Dose Ticagrelor in Patients With Unstable Angina Pectoris After Drug Eluting Stent Implantation Unknown status NCT03620760 Phase 4 Ticagrelor 90 mg;Ticagrelor 45 mg;Aspirin
5 Research on the Clinical Effect of Shuanghe Decoction in Treating Unstable Angina. Unknown status NCT03179527 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Shuanghe Decoction
6 Research on the Clinical Effect of Gualou Xiebai Banxia Decoction Compounded With Danshen Decoction in Treating Unstable Angina. Unknown status NCT03179514 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Gualou Xiebai Banxia Decoction & Danshen Decoction
7 Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina. Unknown status NCT03179618 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction
8 Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
9 Optical Coherence tOmography Based Edge and In-stent Vascular Response After a Novel bioDegradable Polymer sIrolimus-eLuting Stent in patIents With Non-ST Elevation acuTe Coronary sYndrome (NSTE ACS) Unknown status NCT02868203 Phase 4
10 Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly Unknown status NCT02317198 Phase 4 Clopidogrel;Ticagrelor or Prasugrel
11 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
12 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
13 Comparison of Low-dose Heparin Versus Standard Dose Heparin During Coronary Interventions (DEDICA Trial) Unknown status NCT01694459 Phase 4 Low-dose heparin;Standard dose heparin
14 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
15 Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease Unknown status NCT00955214 Phase 4
16 Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes: The Octogenarians Study Unknown status NCT02126202 Phase 4
17 A Randomized, Double-blind, Multicenter, Parallel Controlled Clinical Trial of Danhong Injection in the Treatment of Unstable Angina Pectoris Completed NCT02007187 Phase 4 Danhong injection;Placebo
18 Diagnosis and Treatment of Acute Coronary Syndrome in the Emergency Department- The Impact of Rapid Bedside cTnl on Outcome. Completed NCT00276432 Phase 4
19 Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS) Completed NCT00231738 Phase 4 Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)
20 Differences in the Pharmacokinetic and Pharmacodynamic Profile of Ticagrelor and Its Active Metabolite AR-C124900XX Between Patients With Unstable Angina Pectoris Treated With Crushed Ticagrelor and a Combination of Morphine and Metoclopramide or Morphine Alone - a Randomized Study Completed NCT02939235 Phase 4 Crushed ticagrelor followed by morphine;Crushed ticagrelor, morphine,metoclopramide
21 The Impact of Administration Strategy of Ticagrelor on Its Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris - a Randomized, Single-center, Open-label Pilot Study Completed NCT02612116 Phase 4 Pulverized ticagrelor sublingually;Pulverized ticagrelor orally;Integral ticagrelor
22 Differences in the Pharmacokinetic and Pharmacodynamic Profile of Ticagrelor and Its Active Metabolite AR-C124900XX Between Patients With Unstable Angina Pectoris Treated With Crushed Ticagrelor and a Combination of Morphine and Naloxone or Morphine Alone - a Randomized Study Completed NCT02939248 Phase 4 Crushed ticagrelor followed by morphine;Crushed ticagrelor, morphine,naloxone
23 Phase IV Study Evaluating the Effect of Sitagliptin (Januvia™) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes. Completed NCT00627744 Phase 4 Sitagliptin
24 FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8) Completed NCT00790907 Phase 4 fondaparinux background and standard dose UFH;Fondaparinux background and low dose heparin;Open label fondaparinux
25 Safety and Efficacy of Sustained-Release (SR) Bupropion for Smokers Hospitalized Smokers With Acute Coronary Heart Disease Completed NCT00181818 Phase 4 bupropion SR (sustained-release)
26 Low Restenosis Rate of the NIR Coronary Stent: Results of the Danish Multicenter Stent Study (DANSTENT) - a Randomized Study Comparing a First-Generation With a Second-Generation Stent. Completed NCT00139802 Phase 4
27 Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2) Completed NCT00133003 Phase 4 Abciximab;Placebo
28 A Clinical Trial of Conservative Versus Routine Invasive Management in Patients With Prior Coronary Artery Bypass Surgery in Patients With a Non-ST Elevation Acute Coronary Syndrome: a Pilot Trial and Registry. Completed NCT01895751 Phase 4
29 The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario Completed NCT01066650 Phase 4
30 A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS) Completed NCT00327418 Phase 4 Atorvastatin
31 Multicenter, Randomized, Open Label, Parallel Group Study to Evaluate the Safety and Efficacy of Orsiro Hybrid Drug Eluting Stent Completed NCT01826552 Phase 4
32 The Effect of Intravenous Cangrelor and Oral Ticagrelor on Platelets, the Microcirculation and Myocardial Damage in Patients Admitted With STEMI Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Pilot Trial Completed NCT02733341 Phase 4 Cangrelor;Ticagrelor
33 DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2) Completed NCT01331707 Phase 4
34 Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention(PCI) Completed NCT01293097 Phase 4 Atorvastatin;Statin
35 Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation Completed NCT00905671 Phase 4
36 Prospective, Single-arm, Multicenter Study for Evaluation the Safety and Effectiveness of the ALEX Stent in a Real-world Setting of Percutaneous Coronary Interventions in Patients With Coronary Heart Disease. Study With Angiography and OCT Follow-up. Completed NCT01637012 Phase 4
37 The Effect of Pioglitazone on Neointima Volume and Characteristics Observed by Optical Coherence Tomography (OCT) Completed NCT01331967 Phase 4 Pioglitazone
38 Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial Recruiting NCT03980990 Phase 4 Metformin
39 Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris - METHANE Study Recruiting NCT04442919 Phase 4 Ticagrelor followed with Methoxyflurane;Ticagrelor followed with Morphine;Ticagrelor alone
40 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial Recruiting NCT02601157 Phase 4 3-months DAPT;1-year DAPT
41 Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers In Non ST Elevated acUte Coronary Syndromes With Initial Invasive Indication Active, not recruiting NCT02618837 Phase 4
42 Safety and Efficacy of Low Molecular Weight Heparin Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome(H-REPLACE): a Prospective, Randomized, Open-label, Active-controlled, Multicenter Trial Active, not recruiting NCT03363035 Phase 4 Rivaroxaban 2.5 mg;Rivaroxaban 5 mg;Enoxaparin
43 Implementing Precision Medicine Approaches to Guide Anti-platelet Selection Following Percutaneous Coronary Intervention (PCI) Active, not recruiting NCT04090281 Phase 4
44 Efficacy and Safety of Chinese Herbal Medicine Wen Xin Granules for the Treatment of Unstable Angina Pectoris With Yang Deficiency and Blood Stasis Syndrome: Study Protocol for a Randomized Controlled Trial Not yet recruiting NCT04661709 Phase 4 Wen Xin granule;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Aspirin Enteric-coated Tablets;WXG placebo;Trimetazidine Dihydrochloride Tablets;glyceryl trinitrate
45 A Prospective, Open Label, Randomized, Parallel-group Investigation to Evaluate the Efficacy and Safety of Enoxaparin Versus no Enoxaparin in Subjects With Chest Pain Syndrome and no ECG or Biomarker Abnormalities Terminated NCT00518245 Phase 4 enoxaparin
46 Prospective Randomized Phase IV Open Label Comparative Study Of Dalteparin vs Unfractionated Heparin In High Risk Patients Of Non-ST Elevation Acute Coronary Syndromes Intended For Early Invasive Strategy Terminated NCT00435487 Phase 4 Dalteparin ( Fragmin);Unfractionated heparin
47 A COMparison Between PAClitaxel-coated Balloon and pacliTaxel-eluting Stent in the Treatment of In-Stent Restenosis (COMPACT-ISR) Terminated NCT01204320 Phase 4
48 Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome Terminated NCT02037412 Phase 4 Ticagrelor;Clopidogrel
49 A Randomized Comparative Effectiveness Study of Routine Versus Selective Use of Fractional Flow Reserve (FFR) to Guide Non-Emergent Percutaneous Coronary Intervention (PCI) Terminated NCT02000661 Phase 4
50 Intravenous Isosorbide Dinitrate Versus Sublingual Isosorbide Dinitrate for the Relief of Acute Anginal Episodes in Acute Coronary Syndrome (ACS) Patients Withdrawn NCT00337116 Phase 4 iso sorbide dinitrate iv bolus or s/l

Search NIH Clinical Center for Intermediate Coronary Syndrome

Inferred drug relations via UMLS 70 / NDF-RT 51 :


abciximab
bivalirudin
Dalteparin
Dalteparin Sodium
Enoxaparin
eptifibatide
heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
lepirudin
tirofiban
TIROFIBAN HYDROCHLORIDE

Cochrane evidence based reviews: angina, unstable

Genetic Tests for Intermediate Coronary Syndrome

Anatomical Context for Intermediate Coronary Syndrome

MalaCards organs/tissues related to Intermediate Coronary Syndrome:

40
Endothelial, Heart, Neutrophil, Monocytes, Whole Blood, Brain, T Cells

Publications for Intermediate Coronary Syndrome

Articles related to Intermediate Coronary Syndrome:

(show top 50) (show all 13270)
# Title Authors PMID Year
1
Intracoronary monocyte expression pattern and HDL subfractions after non-ST elevation myocardial infarction. 61
33667626 2021
2
Reduction in acute coronary syndromes during coronavirus disease 2019 global pandemic: data from the Marche region of Italy. 61
33136811 2021
3
Changes in, and predictors of, quality of life among patients with unstable angina after percutaneous coronary intervention. 61
32542918 2021
4
Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based study. 61
33612430 2021
5
The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. 61
33368855 2021
6
The Genetic Variants -717T>C (rs2794521), 1444G>A (rs1130864), and 1846 C > T (rs1205) of CRP Gene, Their Haplotypes, and Their Association with Serum CRP Levels, Acute Coronary Syndrome, and Diabetes in Patients from Western Mexico. 61
33296257 2021
7
Meta-analysis of cardiovascular superiority trials published in the New England Journal of Medicine to elucidate the concept of superiority margin. 61
32156742 2021
8
Differential Vascular Responses to New-Generation Drug-Eluting Stenting According to Clinical Presentation: Three-Month Optical Coherence Tomographic Study. 61
33342226 2021
9
Association Between Plasma ADAMTS-9 Levels and Severity of Coronary Artery Disease. 61
33307720 2021
10
Long Working Hours and Risk of Recurrent Coronary Events. 61
33795035 2021
11
One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration. 61
33515411 2021
12
Trends, Treatment Approaches, and In-Hospital Mortality for Acute Coronary Syndrome in Japan During the Coronavirus Disease 2019 Pandemic. 61
33790127 2021
13
Leuko-platelet index predicts thrombotic events in patients with acute coronary syndrome. 61
33301835 2021
14
Trends in Coded Indications for Percutaneous Coronary Interventions in Medicare and the Veterans Affairs After Implementation of Hospital-Level Reporting of Appropriate Use Criteria. 61
33719490 2021
15
Cost-Effectiveness of Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease and Acute Coronary Syndromes in the US Medicare Program. 61
33787323 2021
16
Impact of left ventricular ejection fraction and preoperative hemoglobin level on perioperative adverse cardiovascular events in noncardiac surgery. 61
33687544 2021
17
Culprit of Unstable Angina: A Large Left Ventricular Outflow Tract Pseudoaneurysm. 61
33706536 2021
18
Epicardial adipose tissue volume predicts long term major adverse cardiovascular events in patients with Type 2 diabetes. 61
33709918 2021
19
Clinical Characteristics and Factors Associated with Poor Outcomes in Hospitalized Patients with Novel Coronavirus Infection COVID-19. 61
33734042 2021
20
Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks. 61
33758291 2021
21
Trace element, immune and opioid biomarkers of unstable angina, increased atherogenicity and insulin resistance: Results of machine learning. 61
33338984 2021
22
A 66-Year-Old Woman with Intermittent Chest Pain and Dyspnea Who Underwent Continued ST-Segment Monitoring to Identify Occult ST-Segment Elevation that Expedited Coronary Angiography and Revascularization. 61
33741889 2021
23
Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice. 61
33712271 2021
24
Characteristics and Prognosis of Patients with Vasospastic Angina Diagnosed by a Provocation Test with Secondary Prevention Implantable Cardioverter Defibrillator. 61
33731515 2021
25
Mean Heart Dose is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the Risk of Major Adverse Cardiac Events in Lung Cancer Radiotherapy. 61
33713743 2021
26
Management of Acute Coronary Syndrome During the MERS-CoV Outbreak - Single-Center Experience. 61
32952079 2021
27
Slow Coronary Flow: Pathophysiology, Clinical Implications, and Therapeutic Management. 61
33779300 2021
28
Treatment of Patients With Recurrent Coronary In-stent Restenosis With Failed Intravascular Brachytherapy. 61
33285089 2021
29
Quantitation of Post-Stress Change in Ventricular Morphology Improves Risk Stratification. 61
33712535 2021
30
Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. 61
33714389 2021
31
Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes. 61
33715025 2021
32
Correlation between 3D-QCA based FFR and quantitative lumen assessment by IVUS for left main coronary artery stenoses. 61
32725862 2021
33
Periodontal Disease Is Associated with Increased Vulnerability of Coronary Atheromatous Plaques in Patients Undergoing Coronary Computed Tomography Angiography-Results from the Atherodent Study. 61
33800969 2021
34
Association of High Density Cholesterol With Hyperemic Epicardial Flow and Frame Count Reserve in Patients With Moderate Coronary Lesions and Slow Coronary Flow. 61
33758725 2021
35
Long-term antiplatelet therapy in medically managed non-ST-segment elevation acute coronary syndromes: The EPICOR Asia study. 61
33186669 2021
36
Serum Bilirubin and Coronary Artery Disease: Intricate Relationship, Pathophysiology, and Recent Evidence. 61
31350011 2021
37
Prognostic Impact of Nonobstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography. 61
33739163 2021
38
The relation between ApoB/ApoA-1 ratio and the severity of coronary artery disease in patients with acute coronary syndrome. 61
33725226 2021
39
Application of medical cannabis in unstable angina and coronary artery disease: A case report. 61
33726006 2021
40
Computed Tomography-Derived Fractional Flow Reserve in Patients With Chronic Coronary Syndrome: A Real-World Cohort Study. 61
33797438 2021
41
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. 61
33755145 2021
42
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. 61
33438437 2021
43
Impact of Age on Gender Difference in Long-term Outcome of Patients With Acute Myocardial Infarction (from J-MINUET). 61
33279486 2021
44
Frequency of ST-segment elevation myocardial infarction, non-ST-segment myocardial infarction, and unstable angina: results from a Southwest Chinese Registry. 61
33792268 2021
45
Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis. 61
33732976 2021
46
Cardiac lymphoma with early response to chemotherapy: A case report and review of the literature. 61
33709334 2021
47
Microbiota thrombus colonization may influence athero-thrombosis in hyperglycemic patients with ST segment elevation myocardialinfarction (STEMI). Marianella study. 61
33453294 2021
48
Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review). 61
33603870 2021
49
An intronic DHCR7 genetic polymorphism associates with vitamin D serum level and incidence of acute coronary syndrome. 61
33741398 2021
50
Nourin-Associated miRNAs: Novel Inflammatory Monitoring Markers for Cyclocreatine Phosphate Therapy in Heart Failure. 61
33808213 2021

Variations for Intermediate Coronary Syndrome

Expression for Intermediate Coronary Syndrome

Search GEO for disease gene expression data for Intermediate Coronary Syndrome.

Pathways for Intermediate Coronary Syndrome

GO Terms for Intermediate Coronary Syndrome

Cellular components related to Intermediate Coronary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.44 SELP PF4 PCSK9 MIR423 MIR342 MIR126
2 cardiac myofibril GO:0097512 9.26 TNNT2 TNNI3
3 cardiac Troponin complex GO:1990584 9.16 TNNT2 TNNI3
4 troponin complex GO:0005861 9.13 TNNT2 TNNT1 TNNI3

Biological processes related to Intermediate Coronary Syndrome according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.73 PCSK9 INS IL6 APOB
2 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.69 SELP MIR126 INS
3 positive regulation of protein kinase B signaling GO:0051897 9.67 P2RY12 MIR126 INS F3
4 positive regulation of gene expression GO:0010628 9.63 PF4 INS IL6 F3 CRP APOB
5 acute-phase response GO:0006953 9.5 INS IL6 CRP
6 positive regulation of leukocyte migration GO:0002687 9.49 SELP ITGA2B
7 negative regulation of ATPase activity GO:0032780 9.48 TNNT2 TNNI3
8 neutrophil mediated immunity GO:0002446 9.46 IL6 ACE
9 muscle filament sliding GO:0030049 9.43 TNNT2 TNNT1 TNNI3
10 negative regulation of lipid storage GO:0010888 9.4 IL6 CRP
11 slow-twitch skeletal muscle fiber contraction GO:0031444 8.96 TNNT1 MB
12 regulation of muscle contraction GO:0006937 8.8 TNNT2 TNNT1 TNNI3

Molecular functions related to Intermediate Coronary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.35 MIR423 MIR342 MIR145 MIR126 MIR106B
2 troponin T binding GO:0031014 9.26 TNNT1 TNNI3
3 troponin C binding GO:0030172 9.16 TNNT2 TNNI3
4 low-density lipoprotein particle receptor binding GO:0050750 8.8 PCSK9 CRP APOB

Sources for Intermediate Coronary Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....